Omeros Q2 2023 net loss $37.3M ($0.59/share); cash $341M; narsoplimab BLA path set

OMEROS CORP

2023-Q2 EPS reported -$1.13

Net loss Q2 2023 $37.3M vs $30.8M prior year; six-month loss $71.0M; cash burn $30.1M.
OMIDRIA royalties $10.7M on Rayner sales $35.7M; rate cut from 50% to 30% after $200M milestone.
Cash, equivalents, and short-term investments $341.3M; accounts receivable $11.2M; runway into 2025.
FDA Type B meeting; plan to submit detailed survival data analysis for narsoplimab BLA in TA-TMA; target mid-2024 decision.
Phase 3 ARTEMIS-IGAN IgA nephropathy 9-month data expected later Q3 2023; OMS906 PNH trial shows positive interim results.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

OMEROS CORP reported second quarter ended June 30, 2023 results: net income Net loss was $37.3 million in the quarter ended June 30, 2023, or $0.59 per share.

Period: second quarter ended June 30, 2023
Net income: Net loss was $37.3 million in the quarter ended June 30, 2023, or $0.59 per share
Result: reported results

Exact text from the filing

Net loss was $37.3 million in the quarter ended June 30, 2023, or $0.59 per share

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

OMEROS CORP reported six months ended June 30, 2023 results: net income For the six months ended June 30, 2023 our net loss was $71.0 million, or $1.13 per share.

Period: six months ended June 30, 2023
Net income: For the six months ended June 30, 2023 our net loss was $71.0 million, or $1.13 per share
Result: reported results

Exact text from the filing

For the six months ended June 30, 2023 our net loss was $71.0 million, or $1.13 per share

View on SEC.gov

Browse all earnings releases →

OMEROS CORP filing history →

Source: SEC EDGAR

accession 0001558370-23-014088

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.